Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB102 in FGF19-overexpressing HCC
NCT07239986Phase 2Not yet recruiting
- Sponsor
- BroadenBio Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BB102 in hepatocellular carcinoma (HCC), sponsored by BroadenBio Co., Ltd.. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
BB102
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07239986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239986.